One for All-Can We Have and Do We Want a First-Line Monotherapy for Epilepsy?
- PMID: 39280050
- PMCID: PMC11394409
- DOI: 10.1177/15357597241227655
One for All-Can We Have and Do We Want a First-Line Monotherapy for Epilepsy?
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Comment on
-
Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.JAMA Neurol. 2023 Nov 1;80(11):1174-1181. doi: 10.1001/jamaneurol.2023.3400. JAMA Neurol. 2023. PMID: 37782485 Free PMC article.
References
-
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375–1386. - PMC - PubMed
-
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363–1374. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources